(AMGN) Amgen’s Vectibix Offers Mixed Data From Trial
Yesterday, Amgen (AMGN) presented data from a phase III trial of its Vectibix in combination with Folfiri (an irinotecan based chemotherapy) as a second-line treatment for metastatic colorectal cancer at the 2009 ECCO 15 – ESMO 34 European Multidisciplinary Congress in Berlin. In the trial, Vectibix significantly improved progression-free survival (PFS) in patients with tumors containing [...] (AMGN) Amgen’s Vectibix Offers Mixed Data From Trial
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here